1. "Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese". Issue 3 (March 2015) Authors: Mele, G.; Melpignano, A.; Quarta, G.; Palumbo, G.; Capalbo, S.; Falcone, A.; Cascavilla, N.; Palazzo, G.; Mazza, P.; Iannitto, E.; Curci, P.; Rizzi, R.; Specchia, G.; Rossini, B.; Pavone, V.; Ria, R.; Vacca, A.; Buquicchio, C.; Tarantini, G.; Minoia, C. Journal: Leukemia research Issue: Volume 39:Issue 3(2015:Mar.) Page Start: 279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. (12th June 2019) Authors: Ferrero, S.; Ladetto, M.; Beldjord, K.; Drandi, D.; Stelitano, C.; Bernard, S.; Castagnari, B.; Bouabdallah, K.; Cesaretti, M.; Alvarez, I.; Gressin, R.; Ponzoni, M.; Tripodo, C.; Traverse‐Glehen, A.; Baseggio, L.; Liberati, A.; Merli, M.; Tessoulin, B.; Patti, C.; Cabras, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PREDICTIVE VALUE OF END‐OF‐TREATMENT POSITRON EMISSION TOMOGRAPHY SCAN AFTER DA‐EPOCH‐R IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA. REAL‐LIFE EXPERIENCE. (12th June 2019) Authors: Derenzini, E.; Ramadan, S.; Vanazzi, A.; Radice, T.; Avenoso, D.; Mulè, A.; Sammassimo, S.; Gigli, F.; Iannitto, E.; Consoli, U.; Patti, C.; Tarella, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗